Tonix Pharmaceuticals (NASDAQ:TNXP) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report sent to investors on Thursday. The brokerage issued a sell rating on the stock.

Separately, Alliance Global Partners lifted their price target on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a buy rating in a report on Monday, July 22nd.

Tonix Pharmaceuticals Trading Up 6.9 %

TNXP opened at $0.15 on Thursday. Tonix Pharmaceuticals has a 12 month low of $0.13 and a 12 month high of $24.16. The stock has a market capitalization of $3.21 million, a price-to-earnings ratio of 0.00 and a beta of 2.09. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.15 and a quick ratio of 0.72. The business has a fifty day moving average price of $0.33 and a 200 day moving average price of $3.12.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Friday, August 16th. The company reported ($19.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($9.91) by ($9.37). The business had revenue of $2.21 million for the quarter, compared to analysts’ expectations of $3.50 million. Tonix Pharmaceuticals had a negative return on equity of 158.27% and a negative net margin of 1,196.11%. Sell-side analysts expect that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.

Institutional Trading of Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC increased its position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the period. Acadian Asset Management LLC owned 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent quarter. Institutional investors and hedge funds own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.